Jury orders Olympus to pay hospital $6.6 million but rejects claims scopes are unsafe

Hospital must pay $1 million to deceased patient’s family


A jury ordered Olympus Corp. to pay a Seattle hospital $6.6 million in damages tied to a deadly superbug outbreak, and told the hospital to pay $1 million to a deceased patient’s family, according to an article on the Los Angeles Times website.

But the jurors rejected claims that the company’s flagship medical scope was unsafe as designed.

The case was filed by Theresa Bigler, 61, and her four children in connection with the August 2013 death of Richard Bigler, a pancreatic cancer patient who contracted an infection linked to a contaminated Olympus TJF-Q180V duodenoscope. 

Virginia Mason Medical Center later joined the suit against Olympus, but the jury found it shared some blame in the case.

Read the article.

 



July 31, 2017


Topic Area: Infection Control


Recent Posts

3 Employees Injured by Patient at Halifax Infirmary's Emergency Department

Police contained the threat and took the patient into custody.


How Architects Shape the Future of Healthcare Facilities

Healthcare architecture is more than just designing and building hospitals.


UNC Health, Duke Health Form Partnership for Stand-alone Children's Hospital

The partners plan to break ground together on the new NC Children’s campus by 2027.


Sarasota Memorial Hospital Plans to Build New Facility in North Port

The six-story, 100-bed hospital is slated to open in fall of 2028.


CMMS, Data and the Path to Compliance

Taking control of healthcare facilities data in CMMS enables managers to use it to ensure the efficient operation and maintenance of their assets.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.